Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics names Terence Rooney chief medical officer, succeeding Jared Gollob

Neutral Impact 4 of 5 leadership Written later

Kymera Therapeutics said Chief Medical Officer Jared Gollob resigned on July 27, 2026, for personal reasons, and will stay on as an advisor through December 31, 2026. Terence Rooney, M.D., formerly an immunology leader at Johnson & Johnson, became CMO effective the same day. The change is a senior management transition that leads clinical development for the company's oral immunology pipeline.

Key points

  • Jared Gollob resigned as Chief Medical Officer on July 27, 2026, after eight years with the company, citing personal reasons
  • Terence Rooney, M.D., succeeds Gollob as CMO effective July 27, 2026
  • Gollob will continue as an advisor until December 31, 2026
  • Rooney previously served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson

The filing

CompanyKymera Therapeutics, Inc. (KYMR)
Form8-K, current report
Filed with the SECJul 27, 2026, 4:10 PM ET
Accession number0001193125-26-318078

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.